Navigation Links
Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Date:8/19/2007

econd quarter of 2007 was 58.2% compared to gross margin of 45.5% in the comparable quarter a year ago. Gross margin for the quarter benefited from the decline in the cost of raw materials for microorganisms and feed additives as well as the production of higher margin new veterinary medicines. The new veterinary medicines have an average gross margin greater than 50%. Skystar expects gross margin to remain in the range of 55%-60%.

Research and development costs were $75,225, or 2.2% of revenue, in the second quarter of 2007 compared to $85,747, or 3.1% of revenue, in the same period a year ago. Skystar's research and development efforts are dedicated to launching new products and developing new technologies to reduce the cost of raw materials.

Selling expenses in the second quarter of 2007 were $148,139, or 4.4% of revenue, compared to $75,574, or 2.7% of revenue, in the same period a year ago. The increase in selling expenses is primarily the result of enhanced marketing and advertising efforts. Skystar expects that selling expenses will

remain at 5%-8% of revenue for the remainder of 2007 as the Company continues to aggressively market its products.

General and administrative ("G&A") expenses were $405,071, or 12.0% of revenue, in the second quarter of 2007, up from $104,835, or 3.8% of revenue, in the second quarter 2006. The increase in G&A expenses reflects professional fees and associated costs of being a U.S. publicly traded company.

Income from operations for the second quarter of 2007 was $1.2 million up 90.0% from $648,651 in the second quarter of 2006. Operating margin for the quarter was 36.5% compared to operating margin of 23.5% in the second quarter of 2006.

Net income for the second quarter of 2007 was $148,311 compared to net income in the second quarter of 2006 of $483,343. Fully diluted earnings per share for the quarter of ($0.22) reflect the non-cash conversion expense of the convertible debentures. Fully dil
'/>"/>

SOURCE Skystar Bio-Pharmaceutical Co.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email: